Medicine
Lotensin HCT 20 mg/12.5 mg tablet
Lotensin HCT 20 mg/12.5 mg tablet is a prescription medicine containing Benazepril and Hydrochlorothiazide for oral use, marketed by Validus Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not store above 86°F (30°C). Protect from moisture and light.
Key facts
- Active ingredient (INN)
- Benazepril and Hydrochlorothiazide
- Brand
- Lotensin HCT
- Strength
- 20 mg/12.5 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets
- Marketing authorisation holder
- Validus Pharmaceuticals
- Manufacturer
- Validus Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Do not store above 86°F (30°C). Protect from moisture and light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 May 1992
- Identifiers
- RxCUI 898362, 898366, 898367 +3DailyMed set ID 94c4536f-e28e-48b1-8336-b3939917e99dNDC 30698-453Application NDA020033
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet in 1 bottle | 30698-453-01 | Validus Pharmaceuticals | 30 May 1992 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 19 May 1992 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Benazepril and Hydrochlorothiazide 20 mg/12.5 mg tablet.
Other strengths and forms of Benazepril and Hydrochlorothiazide
Clinical summary
Benazepril and Hydrochlorothiazide is a fixed-dose combination of an angiotensin converting enzyme inhibitor and a thiazide diuretic indicated for the treatment of hypertension. It is available as tablets for oral use. MedsAcross supplies Benazepril and Hydrochlorothiazide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Benazepril and HydrochlorothiazideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- benazepril hydrochloride and hydrochlorothiazide prescribing information (Advagen Pharma) · U.S. National Library of Medicine, DailyMed
Need Lotensin HCT 20 mg/12.5 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.